In this article, we will look specifically at the development challenge faced when moving a peptide-drug conjugate (PDC) from pre-clinical (gram-scale) to phase I (kg-scale). New modality conjugations with HPAPIs and peptides – particularly for oncology targets – are now an increasingly large part of the discovery pipeline.
